2018
DOI: 10.1016/j.ejca.2018.09.024
|View full text |Cite
|
Sign up to set email alerts
|

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
57
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 74 publications
(61 citation statements)
references
References 24 publications
2
57
0
Order By: Relevance
“…In the present study, we demonstrated that in three out of seven patients (42.9%), HER2-positive tumor cells in resected specimens disappeared after trastuzumab-based chemotherapy. To date, several investigators have reported the loss of HER2 positivity in 29%-61% of biopsied tumors and 21%-42% of surgical specimens obtained from patients with gastric cancer, after trastuzumab-based chemotherapy (16)(17)(18)(19)(20). Consequently, these results are consistent with our findings showing loss of HER2 positivity (42.9%).…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…In the present study, we demonstrated that in three out of seven patients (42.9%), HER2-positive tumor cells in resected specimens disappeared after trastuzumab-based chemotherapy. To date, several investigators have reported the loss of HER2 positivity in 29%-61% of biopsied tumors and 21%-42% of surgical specimens obtained from patients with gastric cancer, after trastuzumab-based chemotherapy (16)(17)(18)(19)(20). Consequently, these results are consistent with our findings showing loss of HER2 positivity (42.9%).…”
Section: Discussionsupporting
confidence: 92%
“…The third key issue is the effect of formalin fixation conditions. Saeki et al reported that the use of fixatives other than 10% neutral buffered-formalin significantly reduce the HER2 overexpression rate (18). In the present study, neutral buffered-formalin at 10% and 20% was used for HER2 IHC in six and one out of seven patients, respectively.…”
Section: Discussionmentioning
confidence: 65%
“…Studies that evaluated changes in HER2 protein expression in AGC patients receiving trastuzumab-containing regimens by comparison of matched pre-and post-treatment samples have demonstrated a loss of HER2 [33,34]. In the aforementioned T-ACT study [21], given that collection of new tumor biopsy samples at the time of study enrollment (after progression on prior trastuzumab therapy) was not mandatory, reassessment of HER2 positivity was performed for only 16 out of 44 patients.…”
Section: Loss Of Her2 Protein Expressionmentioning
confidence: 99%
“…Results of a phase II study comparing the combination of paclitaxel with beyond progression trastuzumab versus paclitaxel alone in Her2 positive patients, who already received first line antibody/chemotherapy combination therapy, showed that there was no benefit of combination therapy concerning the overall survival (9.95 months with paclitaxel versus 10.2 months in the paclitaxel + trastuzumab arm; HR = 1.23; 95% CI 0.75-1.99; p = 0.20) [64]. It is surmised that this effect might be due to the loss of HER2 after first line treatment, since almost 2/3 of patients lost their Her2 positivity, which was evaluated in an additional biopsy at the time of progression under trastuzumab [64,65]. However, some new retrospective analyses suggest that although there is no improvement of the OS, patients might still have a clinical benefit from the continuation of Trastuzumab beyond first-line progression [66,67].…”
Section: Her2 Positive Gastroesophageal Tumoursmentioning
confidence: 99%